KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Other Non Operating Income: 2012-2023

Historic Other Non Operating Income for TherapeuticsMD (TXMD) over the last 10 years, with Sep 2023 value amounting to $359,000.

  • TherapeuticsMD's Other Non Operating Income rose 420.54% to $359,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $880,000, marking a year-over-year increase of 110.35%. This contributed to the annual value of -$117,000 for FY2022, which is 143.01% down from last year.
  • According to the latest figures from Q3 2023, TherapeuticsMD's Other Non Operating Income is $359,000, which was up 248.54% from $103,000 recorded in Q2 2023.
  • In the past 5 years, TherapeuticsMD's Other Non Operating Income ranged from a high of $703,662 in Q3 2019 and a low of -$10.1 million during Q2 2019.
  • Over the past 3 years, TherapeuticsMD's median Other Non Operating Income value was $19,000 (recorded in 2021), while the average stood at -$668,727.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first skyrocketed by 35,969.57% in 2020, then crashed by 6,968.85% in 2022.
  • TherapeuticsMD's Other Non Operating Income (Quarterly) stood at -$368 in 2019, then surged by 35,969.57% to $132,000 in 2020, then slumped by 93.94% to $8,000 in 2021, then spiked by 37.50% to $11,000 in 2022, then soared by 420.54% to $359,000 in 2023.
  • Its Other Non Operating Income stands at $359,000 for Q3 2023, versus $103,000 for Q2 2023 and $407,000 for Q1 2023.